Press Releases H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 08/05/2026 pm IST			5-day change	1st Jan Change
43.06 ^DKK	+0.19%		+1.56%	-0.23%

28/04	SEB raises Lundbeck price target to DKK 46 (43), reiterates Hold	FW
27/04	UBS raises Lundbeck price target to DKK 44 (42), reiterates Neutral	FW

Press Releases

19/04	Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)	AQ
13/04	Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting	AQ
30/03	H Lundbeck A/S : Remuneration Policy 2026 (Remuneration Policy 2026)	PU
18/03	Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office	AQ
18/03	H Lundbeck A/S : Presentation (AGM Presentation 2026)	PU
16/03	Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026	AQ
10/03	Lundbeck appoints Chief AI Officer	AQ
09/03	Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial	AQ
17/02	H Lundbeck A/S : Remuneration Report 2025 (Remuneration Report 2025)	PU
17/02	H Lundbeck A/S : Registration form (Registration form)	PU
17/02	H Lundbeck A/S : Annual Report 2025 (Annual Report)	PU
17/02	H Lundbeck A/S : Appendix 1 Amended Remuneration Policy 2026 (Appendix 1 Amended Remuneration Policy 2026)	PU
17/02	To the shareholders of H. Lundbeck A/S	AQ
12/02	Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention	AQ
10/02	H Lundbeck A/S : Transcript (Transcript FY25)	PU
04/02	Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	AQ
04/02	H Lundbeck A/S : Annual Report (Lundbeck Annual Report 2025)	PU
04/02	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck FY 2025 1)	PU
04/02	H Lundbeck A/S : Release (Corporate Release FY2025 Final)	PU
04/02	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck FY 2025)	PU
04/02	Lundbeck Annual Report 2025	AQ
04/02	Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026	AQ
30/01	Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference	AQ
08/12	Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	AQ
06/12	Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting	AQ